Tirzepatide half-life & pharmacokinetics

Reported half-life

Approximately 116-120 hours (~5 days) plasma half-life through covalent C20 fatty diacid binding to circulating serum albumin. Supports once-weekly subcutaneous dosing. Slightly shorter than semaglutide's 7-day half-life but sufficient for the same dosing interval. Steady-state plasma concentrations are reached after approximately 4 weekly doses.

The half-life and pharmacokinetic profile of Tirzepatide reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (once weekly; licensed route)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Long-acting synthetic dual GIPR/GLP-1R co-agonist; MHRA-licensed medicinal product for type-2 diabetes and chronic weight management.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Tirzepatide acts as follows:

Tirzepatide is a 39-amino-acid synthetic peptide engineered as the first commercially successful dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). The molecular design started from the native GIP sequence — chosen as the structural backbone because the native GLP-1 backbone proved less amenable to engineering high-affinity GIPR binding — with systematic substitutions to introduce GLP-1R cross-reactivity while preserving GIPR affinity. The result is a chimeric peptide that binds both receptors as a full or near-full agonist, with affinities approximately 5-fold higher at GIPR than at GLP-1R relative to the respective native ligands.

See the full Tirzepatide research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.